Literature DB >> 7437210

Infusion model for fentanyl based on pharmacokinetic analysis.

J H Hengstmann, H Stoeckel, J Schüttler.   

Abstract

The calculation of pharmacokinetic parameters after a bolus injection of fentanyl allowed an i.v. infusion scheme which guarantees analgesia for the entire duration of surgery, with the advantage of steady plasma concentration and body content. In the initial phase after bolus injection, the serum concentration decreased rapidly for about 10 min, indicating extensive transfer to the peripheral compartment. This was followed by a slower elimination phase with a half-life of about 2 h. The total volume of distribution of 80 litre exceeded the body weight only slightly. The total plasma clearance was 500ml min-1. In developing a model for total i.v. anaesthesia we considered two different consecutive infusion rates. The pharmacokinetic model proved to be valid for all patients. The plasma concentrations duration anaesthesia coincided well with the predicted steady state plasma concentrations and provided continuous analgesia during operation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437210     DOI: 10.1093/bja/52.10.1021

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent.

Authors:  D P Crankshaw; N E Edwards; G L Blackman; M D Boyd; H N Chan; D J Morgan
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Fentanyl-oxygen versus fentanyl-N2O/oxygen anaesthesia in children undergoing cardiac surgery.

Authors:  P Crean; G Koren; G Goresky; J Klein; S Macleod
Journal:  Can Anaesth Soc J       Date:  1986-01

Review 4.  Clinical pharmacokinetics of fentanyl and its newer derivatives.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.